Background: The need for therapeutically effective anticancer drug delivery systems constantly
persuades researchers to explore novel strategies.
Objective: In this study a novel cubane based antibacterial nanocomposite was tailored as dual chemotherapy
drug delivery vesicle in order to increase the therapeutic outcome in cancer therapy.
Method: The physico-chemical characterization of engineered nanocarrier was assessed by Fourier transforms
infrared spectroscopy (FTIR), Hydrogen nuclear magnetic resonance spectroscopy (1H NMR), Thermogravimetric
analysis (TGA), and Field emission scanning electron microscopy-energy dispersive using X-ray (FESEMEDX).
The antibacterial activity of novel developed nanocomposite was tested by determining minimum inhibitory
concentration (MIC) values against Pseudomonas aeruginosa, Escherichia Coli and Candida albicans.
Results: In order to investigate the efficacy of novel engineered nanocomposite (with average particle size of 50
nm) as dual anticancer drug delivery, DOX and MTX were bind to nanocarrier with encapsulation efficiency
and loading content of around 97.3 ± 2.7% and 20.8 ± 1.6 %, respectively. Dual drugs released simultaneously
with distinct tumor targeted, pH responsive sustained release manner. Moreover, the probable antitumoral activity
of this engineered nanocomposite system against MCF7 cell lines was evaluated by MTT assay and cell
cycle studies. The outcomes showed that novel engineered nanocomposite had no cytotoxic effects, while
DOX@MTX-loaded nanocomposite possessed higher growth inhibition property and higher S-phase arrest as
compared to cells treated with DOX@MTX alone.
Conclusion: It was concluded that this novel cubane based drug delivery vehicle could process antibacterial and
anticancer therapeutics spontaneously, representing promising tumor targeted system in nanomedicine.